TENX Insider Trading
Insider Ownership Percentage: 3.14%
Insider Buying (Last 12 Months): $149,053.47
Insider Selling (Last 12 Months): $0.00
Tenax Therapeutics Share Price & Price History
Current Price: $16.05
Price Change: ▲ Price Increase of +0.15 (0.94%)
As of 01/16/2026 05:00 PM ET
Tenax Therapeutics Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 12/8/2025 | Stuart Rich | Insider | Buy | 2,500 | $10.10 | $25,250.00 | 5,000 | |
| 12/4/2025 | Stuart Rich | Insider | Buy | 2,500 | $9.20 | $23,000.00 | 2,500 | |
| 12/3/2025 | Stuart Rich | Insider | Buy | 1,500 | $9.08 | $13,620.00 | 2,766 | |
| 12/2/2025 | Stuart Rich | Insider | Buy | 1,000 | $9.01 | $9,010.00 | 1,266 | |
| 11/20/2025 | Christopher Thomas Giordano | CEO | Buy | 538 | $7.59 | $4,083.42 | 2,605 | |
| 11/19/2025 | Christopher Thomas Giordano | CEO | Buy | 455 | $7.51 | $3,417.05 | 2,067 | |
| 11/18/2025 | Christopher Thomas Giordano | CEO | Buy | 1,612 | $7.75 | $12,493.00 | 1,612 | |
| 11/17/2025 | Thomas Mcgauley | CFO | Buy | 2,000 | $7.34 | $14,680.00 | 2,000 | |
| 11/17/2025 | Thomas Mcgauley | CFO | Buy | 6,000 | $7.25 | $43,500.00 | 5,000 | |
Tenax Therapeutics Institutional Trading History
| Reporting Date | Hedge Fund | Shares Held | Market Value | % of Portfolio | Quarterly Change in Shares | Ownership in Company | Details |
|---|
| 11/17/2025 | Woodline Partners LP | 88,211 | $0.67M | 0.0% | N/A | 1.933% |  |
| 11/17/2025 | Millennium Management LLC | 313,712 | $2.39M | 0.0% | +34.2% | 6.875% |  |
| 11/17/2025 | Citadel Advisors LLC | 43,253 | $0.33M | 0.0% | +318.1% | 0.948% |  |
| 11/17/2025 | Boothbay Fund Management LLC | 352,206 | $2.68M | 0.0% | N/A | 7.719% |  |
| 11/14/2025 | Virtu Financial LLC | 12,119 | $92K | 0.0% | N/A | 0.266% |  |
| 11/14/2025 | ADAR1 Capital Management LLC | 53,428 | $0.41M | 0.0% | -65.7% | 1.171% |  |
| 5/16/2025 | ADAR1 Capital Management LLC | 68,741 | $0.45M | 0.1% | +98.1% | 1.657% |  |
| 2/17/2025 | Vestal Point Capital LP | 55,189 | $0.34M | 0.0% | -33.8% | 1.618% |  |
| 2/17/2025 | Two Sigma Investments LP | 13,521 | $84K | 0.0% | N/A | 0.397% |  |
| 2/17/2025 | Millennium Management LLC | 26,809 | $0.17M | 0.0% | N/A | 0.786% |  |
| 2/17/2025 | Janus Henderson Group PLC | 166,666 | $1.03M | 0.0% | N/A | 4.888% |  |
| 2/13/2025 | ADAR1 Capital Management LLC | 34,693 | $0.22M | 0.0% | -44.4% | 1.017% |  |
| 2/12/2025 | Geode Capital Management LLC | 24,354 | $0.15M | 0.0% | +32.4% | 0.714% |  |
| 11/15/2024 | Sphera Funds Management LTD. | 29,166 | $0.10M | 0.0% | N/A | 0.855% |  |
| 11/14/2024 | Vestal Point Capital LP | 83,333 | $0.29M | 0.0% | N/A | 2.444% |  |
| 11/14/2024 | Stonepine Capital Management LLC | 50,000 | $0.17M | 0.1% | N/A | 1.466% |  |
| 5/1/2023 | Virtu Financial LLC | 84,361 | $39K | 0.0% | N/A | 0.377% |  |
| 11/14/2022 | Armistice Capital LLC | 1,965,885 | $0.33M | 0.0% | +23.1% | 7.799% |  |
| 11/5/2021 | PNC Financial Services Group Inc. | 70,000 | $0.12M | 0.0% | N/A | 0.278% |  |
Data available starting January 2016
Tenax Therapeutics, Inc. develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is based in Chapel Hill, North Carolina.
Read More on Tenax Therapeutics
Today's Range
Now: $16.05
52 Week Range
Now: $16.05
Volume
165,745 shs
Average Volume
296,334 shs
Market Capitalization
$100.15 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.34
Who are the company insiders with the largest holdings of Tenax Therapeutics?